iBio (NYSEAMERICAN:IBIO) is expanding its horizons. In addition to being way behind in the race to develop a coronavirus vaccine, it’s now also way behind in the race to develop a coronavirus treatment. Despite the company’s decision to diversify its business, I remain bearish on IBIO stock at this point. Source: Shutterstock.com As many other
Stocks to sell
Its been the year of the special purpose acquisition company (SPAC). Over 50 SPACs have been formed in 2020 alone, and they have raised over $21.5 billion. Spartan Energy Acquisition (NYSE:SPAQ) is one of the top SPACs in the market, as SPAQ stock has jumped 40% so far this year. Source: Shutterstock The company’s big
When Nio (NASDAQ:NIO) staged an incredible rally for the week, rising from around $14 to a 52-week high of $20.97, management took advantage of the rise. The company announced a proposed offering of 75 million American Depository Shares (“ADS”) on Aug. 27. Underwriters may buy another 11.25 million ADRs. Nio fell a pronounced 6.94% the
In a prior article, I said that Docusign (NASDAQ:DOCU) was a company that will continue to grow regardless of the pandemic. Secure, electronic signatures are simply an idea whose time has come. And it has become essential technology for many online businesses. But should you buy Docusign stock at its current price? The technicals are
Riding high thanks to the EV bubble, what’s next for Plug Power (NASDAQ:PLUG) and PLUG stock? A rising star in the hydrogen fuel cell (HFC) space, shares are up 309% so far this year. While the company’s prospects appear strong, lingering concerns remain. Source: petrmalinak / Shutterstock.com What do I mean? Firstly, valuation. Granted, valuation
The onset of the novel coronavirus put enormous pressure on the U.S. stock market, but not all businesses were impacted equally. If you had to choose one company that thrived the most during the pandemic, a reasonable choice would be Zoom Video Communications (NASDAQ:ZM). At the same time, ZM stock holders easily outperformed the major market
Bouncing back after cratering earlier this month, should you dive into iBio (NYSEAMERICAN:IBIO)? Not so fast! Investors now may be buyyng on the headlines thanks to a potentially positive development. But make no mistake—this isn’t time to “buy the dip” on iBio stock. Source: Shutterstock Why? Sure, the company remains a contender in the race
Over the last few weeks, shares of Ocugen (NASDAQ:OCGN) stock rocketed nearly 420% to a July 2020 high of about 96 cents. Then it was more than halved to 40 cents. Source: Shutterstock So is the life of a volatile penny stock. The only reason the stock popped was because its lead gene therapy drug,
InvestorPlace’s Bret Kenwell recently wrote an article about Exxon Mobil (NYSE:XOM) stock entitled By Maintaining Its Dividend, Exxon Mobil Stock Is an Energy Name to Hold. Source: Michael Gordon / Shutterstock.com Bret makes excellent points about why an investor might want to bite into its juicy dividend yield. Now, to be clear, Bret likes to
Marathon Patent Group (NASDAQ:MARA) has had an interesting run. A few years ago, the company tried to commercialize intellectual property, as you might guess from its name. However, when that didn’t pan out, Marathon made an abrupt pivot to cryptocurrency mining in 2017. MARA stock briefly soared. Source: Shutterstock That excitement soon fizzled though. As
In an expansive universe of U.S.-listed Chinese equities and cloud computing names, Taoping (NASDAQ:TAOP) isn’t the one to consider. On either account. If you haven’t heard of Tapoing stock, that’s alright. In this case, ignorance may be bliss. Source: Shutterstock The company has two primary businesses segments: traditional information technology and cloud computing, where it operates
Despite the ravages of the novel coronavirus, some retail apparel companies have performed very well this year. Thanks to a combination of compelling products and social awareness, the pandemic has so far been a net positive for certain brands. Unfortunately, investors cannot say the same about Under Armour (NYSE:UA, NYSE:UAA). Its toxicity was bad enough
Investors typically look at gold and other precious metals in times of market turmoil. Naturally, gold has become a safe haven for investors as the novel coronavirus changes the landscape of financial markets. Hence, investors are clamoring to buy gold stocks as gold prices have risen 27% year to date. However, things have not been
When I last weighed in on Chesapeake Energy (OTCMKTS:CHKAQ), I said, “Bankruptcy is in the offing, as the energy firm buckles under far too much debt.” That was back in May 2020, as Chesapeake Energy stock traded at $31 after a 200:1 reverse split. Source: IgorGolovniov / Shutterstock.com But that was a no-brainer observation. With high
iBio Pharma (NYSEAMERICAN:IBIO) remains behind in the world’s vaccine quest. And just as quickly as it rose, IBIO stock is quickly fading into irrelevance. Source: Shutterstock The company’s FastPharming platform, using plant-based protein production, is unique and interesting. I can see how theoretically it could be used to quickly mass-produce a novel coronavirus vaccine. But
Berkshire Hathaway’s (NYSE:BRK.A, NYSE:BRK.B) second-quarter 13F report says all you need to know about Occidental Petroleum (NYSE:OXY) and OXY stock. Source: Pavel Kapysh / Shutterstock.com You shouldn’t own it. It’s that simple. After Warren Buffett threw in the towel on OXY stock, the average investor has no business jumping into this quagmire of a stock.
Even with the novel coronavirus taking a major toll on the economy, some businesses are weathering the financial storm. Costco (NASDAQ:COST) is an excellent example of this, as consumers continue to flock to the discount retailer for essential items. As a result, the Costco stock price has maintained a steady upward trajectory in recent months.
It seems that every week or so, another pharmaceutical company announces a breathtaking, breathless breakthrough on the way to perfecting a vaccine for the novel coronavirus. And those who’ve monitored Inovio (NASDAQ:INO) stock know how crowded the field is: At least 15 companies are vying to cross the finish line first. It’s enough to conjure
Shares of Ford (NYSE:F) are a lot like sugar cookies. They aren’t expensive and hey, it’s a long time until dinner. Meanwhile, there’s little nutritional value and the blast of sugar isn’t healthy. F stock, these days, is more like a cheap cookie without the sweet taste. That may be OK if you’re seeking a
By any conventional measure Amazon (NASDAQ:AMZN) is overvalued. With a market cap of $1.66 trillion, AMZN stock is being valued at over four times its potential 2020 revenue of $400 billion. That’s based on its second quarter sales of $101 billion. Source: Jonathan Weiss / Shutterstock.com It’s not unusual to value a tech company at 10